INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 170 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2016. The put-call ratio across all filers is 0.95 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $602,000 | -30.1% | 12,560 | -8.1% | 0.01% | -42.9% |
| Q1 2020 | $861,000 | -42.3% | 13,660 | +8.8% | 0.01% | -6.7% |
| Q4 2019 | $1,491,000 | +78.8% | 12,560 | 0.0% | 0.02% | +66.7% |
| Q3 2019 | $834,000 | -18.6% | 12,560 | -2.3% | 0.01% | -18.2% |
| Q2 2019 | $1,024,000 | +509.5% | 12,860 | +757.3% | 0.01% | +450.0% |
| Q1 2019 | $168,000 | +479.3% | 1,500 | +200.0% | 0.00% | – |
| Q4 2017 | $29,000 | 0.0% | 500 | 0.0% | 0.00% | – |
| Q3 2017 | $29,000 | -52.5% | 500 | 0.0% | 0.00% | -100.0% |
| Q2 2017 | $61,000 | +7.0% | 500 | 0.0% | 0.00% | – |
| Q1 2017 | $57,000 | +5600.0% | 500 | +24900.0% | 0.00% | – |
| Q3 2016 | $1,000 | 0.0% | 2 | 0.0% | 0.00% | – |
| Q2 2016 | $1,000 | 0.0% | 2 | -50.0% | 0.00% | – |
| Q1 2016 | $1,000 | 0.0% | 4 | +100.0% | 0.00% | – |
| Q4 2015 | $1,000 | – | 2 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |